Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by J. Wang
Based on 7 articles published since 2010
(Why 7 articles?)
||||

Between 2010 and 2020, J. Wang wrote the following 7 articles about Pancreatic Neoplasms.
 
+ Citations + Abstracts
1 Review Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. 2017

Gilbert, J W / Wolpin, B / Clancy, T / Wang, J / Mamon, H / Shinagare, A B / Jagannathan, J / Rosenthal, M. ·Department of Imaging, Dana-Farber Cancer Institute. · Department of Radiology, Brigham and Women's Hospital. · Harvard Medical School. · Department of Medical Oncology, Dana-Farber Cancer Institute. · Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital. · Gastrointestinal Surgical Center, Dana-Farber/Brigham and Women's Cancer Center. · Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA. ·Ann Oncol · Pubmed #28407088.

ABSTRACT: Background: Diagnostic imaging plays a critical role in the initial diagnosis and therapeutic monitoring of pancreatic adenocarcinoma. Over the past decade, the concept of 'borderline resectable' pancreatic cancer has emerged to describe a distinct subset of patients existing along the spectrum from resectable to locally advanced disease for whom a microscopically margin-positive (R1) resection is considered relatively more likely, primarily due to the relationship of the primary tumor with surrounding vasculature. Materials and methods: This review traces the conceptual evolution of borderline resectability from a radiological perspective, including the debates over the key imaging criteria that define the thresholds between resectable, borderline resectable, and locally advanced or metastatic disease. This review also addresses the data supporting neoadjuvant therapy in this population and discusses current imaging practices before and during treatment. Results: A growing body of evidence suggests that the borderline resectable group of patients may particularly benefit from neoadjuvant therapy to increase the likelihood of an ultimately margin-negative (R0) resection. Unfortunately, anatomic and imaging criteria to define borderline resectability are not yet universally agreed upon, with several classification systems proposed in the literature and considerable variance in institution-by-institution practice. As a result of this lack of consensus, as well as overall small patient numbers and lack of established clinical trials dedicated to borderline resectable patients, accurate evidence-based diagnostic categorization and treatment selection for this subset of patients remains a significant challenge. Conclusions: Clinicians and radiologists alike should be cognizant of evolving imaging criteria for borderline resectability given their profound implications for treatment strategy, follow-up recommendations, and prognosis.

2 Article Differential MicroRNA Expression Profiles as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma. 2019

Zhu, Y / Wang, J / Wang, F / Yan, Z / Liu, G / Ma, Y / Zhu, W / Li, Y / Xie, L / Bazhin, A V / Guo, X. ·Department of Oncology, International Joint Laboratory for Cell Medical Engineering of Henan Province, Henan University Huaihe Hospital, Kaifeng, Henan, 475000, P. R. China. celltransplant@163.com. · Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014, P. R. China. wj68happy@hotmail.com. · Department of Preventive Medicine, Cell Signal Transduction Laboratory, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan University, Kaifeng, Henan, 475004, P. R. China. · Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450014, P. R. China. · College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, Tianjin, 300353, P. R. China. mayonggang@nankai.edu.cn. · Department of Anesthesia, Stanford University, CA 94305, USA. wan.zhu@stanford.edu. · Department of General, Visceral, and Transplantation Surgery, Ludwig-Maximilians-University Munich, Munich, 81377, Germany. alexandr.bazhin@med.uni-muenchen.de. · Department of Preventive Medicine, Cell Signal Transduction Laboratory, Joint National Laboratory for Antibody Drug Engineering, Institute of Biomedical Informatics, Medical School, Henan University, Kaifeng, Henan, 475004, P. R. China. xqguo@henu.edu.cn. ·Biochemistry (Mosc) · Pubmed #31234772.

ABSTRACT: Pancreatic ductal adenocarcinoma (PDAC) remains a clinical challenge due to its poor prognosis. Therefore, the early diagnosis of PDAC is extremely important for achieving a cure. MicroRNAs (miRNAs) could serve as a potential biomarker for the early detection and prognosis of PDAC. In this work we analyzed plasma samples from healthy persons and PDAC patients to assess differential miRNA expression profiles by next generation sequencing technology and bioinformatics analysis. In this way, 165 mature miRNAs were found to be significantly deregulated in the patient group, of which 75 and 90 mature miRNAs were up- and down-regulated compared with healthy individuals, respectively. Furthermore, 1029 novel miRNAs were identified. In conclusion, plasma miRNA expression profiles are different between healthy individuals and patients with PDAC. These data provide a possibility for use of miRNA as diagnostic and prognostic biomarkers of PDAC.

3 Article [Expression of B cell transposition gene 3 in pancreatic ductal adenocarcinoma and its prognostic value]. 2017

Chen, J / Zhou, Z C / Liu, W B / Wang, J / Chen, X J / Shen, Y Y / Zhong, Z X. ·Department of Hepatobiliary Surgery, Second Hospital of Jiaxing Affiliated to Jiaxing University, Jiaxing 314000, Zhejiang Province, China. ·Zhonghua Wai Ke Za Zhi · Pubmed #29136736.

ABSTRACT:

4 Article Percutaneous computed tomography-guided iodine-125 seeds implantation for unresectable pancreatic cancer. 2015

Liu, B / Zhou, T / Geng, J / Zhang, F / Wang, J / Li, Y. ·Department of Interventional Medicine, The Second Hospital of Shandong University, Shandong, Shandong Province, PR of, China. ·Indian J Cancer · Pubmed #26728678.

ABSTRACT: BACKGROUND: To examine the safety and clinical efficacy of computed tomography (CT)-guided radioactive iodine-125 (125I) seeds implantation for patients with unresectable pancreatic cancer. MATERIALS AND METHODS: A group of 26 patients with pathologically confirmed unresectable pancreatic cancer underwent percutaneous CT-guided 125I seeds implantation. Part of them received transarterial chemotherapy and/or percutaneous transhepatic cholangial drainage before or after seeds implantation. The primary endpoints were the objective response rates, local control rates, and overall survival. RESULTS: CT scan 2 months after treatment revealed complete response (CR) in 8 patients, partial response (PR) in 9 patients. Overall response rate (CR + PR) is 65.38%. Local control rate was 88.46%. Median survival of the whole group was 15.3 months, whereas for Stage III and IV was 17.6 and 9.1 months, respectively. The estimated 1-year survival was 30.77%. CONCLUSIONS: We consider CT-guided 125I seeds implantation as a safe, effective, uncomplicated treatment for unresectable pancreatic cancer.

5 Article Pharmacological inhibition of Eph receptors enhances glucose-stimulated insulin secretion from mouse and human pancreatic islets. 2013

Jain, R / Jain, D / Liu, Q / Bartosinska, B / Wang, J / Schumann, D / Kauschke, S G / Eickelmann, P / Piemonti, L / Gray, N S / Lammert, E. ·Institute of Metabolic Physiology and German Diabetes Center, Heinrich-Heine University Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany. ·Diabetologia · Pubmed #23475368.

ABSTRACT: AIMS/HYPOTHESIS: Type 2 diabetes is characterised by impaired glucose-stimulated insulin secretion (GSIS) from pancreatic islets. Since erythropoietin-producing hepatoma (Eph)-ephrin bidirectional signalling fine-tunes GSIS from pancreatic beta cells, we investigated Eph receptor tyrosine kinases (RTK) as potential drug targets for selectively increasing GSIS. METHODS: Insulin secretion assays were carried out using mouse and human pancreatic islets as well as mouse insulinoma (MIN6) cells in the presence or absence of two Eph RTK inhibitors. Furthermore, the most potent inhibitor was injected into mice to evaluate its effects on glucose tolerance and plasma insulin levels. RESULTS: We showed that the Eph RTK inhibitors selectively increased GSIS from MIN6 cells as well as mouse and human islets. Our results also showed that the insulin secretory effects of these compounds required Eph-ephrin signalling. Finally, pharmacological inhibition of Eph receptor signalling improved glucose tolerance in mice. CONCLUSIONS/INTERPRETATION: We showed for the first time that Eph RTKs represent targets for small molecules to selectively increase GSIS and improve glucose tolerance.

6 Article Gemcitabine adsorbed onto carbon particles increases drug concentrations at the injection site and in the regional lymph nodes in an animal experiment and a clinical study. 2011

Guo, F / Mao, X / Wang, J / Luo, F / Wang, Z. ·Department of General Surgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. ·J Int Med Res · Pubmed #22289537.

ABSTRACT: This study investigated whether gemcitabine, adsorbed onto activated carbon particles (GEM-AC), increased the concentration of gemcitabine at the injection site and in the regional lymph nodes in an experimental animal model and a clinical study. The adsorption isotherm for GEM-AC was defined, and the concentration and distribution of gemcitabine in rats (n = 50) and in patients with pancreatic cancer (n = 8) was investigated. Drug concentrations in plasma, tumour samples, lymph nodes and at the injection site were measured after GEM-AC or gemcitabine solution (GEM-Sol) were subcutaneously injected into the left hind foot pad in rats, or into pancreatic tumours in patients. These experiments showed that GEM-AC was selectively delivered to the regional lymph nodes and the injection site, from which it slowly released greater amounts of gemcitabine to maintain the free concentration of gemcitabine at a relatively high level for a long period of time. The administration of GEM-AC might enhance the anticancer effects of gemcitabine.

7 Minor Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al. 2017

Gilbert, J W / Wolpin, B / Clancy, T / Wang, J / Mamon, H / Shinagare, A B / Jagannathan, J / Rosenthal, M. ·Department of Imaging, Dana-Farber Cancer Institute, Boston. · Department of Radiology, Brigham and Women's Hospital, Boston. · Harvard Medical School, Boston. · Department of Medical Oncology, Dana-Farber Cancer Institute, Boston. · Division of Surgical Oncology, Department of Surgery, Brigham and Women's Hospital and Gastrointestinal Surgical Center, Dana-Farber/Brigham and Women's Cancer Center, Boston. · Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, USA. ·Ann Oncol · Pubmed #28541392.

ABSTRACT: -- No abstract --